文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

间隔队列设计和对方案效应估计的偏倚:一项模拟研究。

Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.

机构信息

Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, USA.

Pathways M.D. Program, Harvard Medical School, Boston, USA.

出版信息

Trials. 2019 Sep 5;20(1):552. doi: 10.1186/s13063-019-3577-z.


DOI:10.1186/s13063-019-3577-z
PMID:31488202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6729016/
Abstract

BACKGROUND: Randomized trials are considered the gold standard for making inferences about the causal effects of treatments. However, when protocol deviations occur, the baseline randomization of the trial is no longer sufficient to ensure unbiased estimation of the per-protocol effect: post-randomization, time-varying confounders must be sufficiently measured and adjusted for in the analysis. Given the historical emphasis on intention-to-treat effects in randomized trials, measurement of post-randomization confounders is typically infrequent. This may induce bias in estimates of the per-protocol effect, even using methods such as inverse probability weighting, which appropriately account for time-varying confounders affected by past treatment. METHODS/DESIGN: In order to concretely illustrate the potential magnitude of bias due to infrequent measurement of time-varying covariates, we simulated data from a very large trial with a survival outcome and time-varying confounding affected by past treatment. We generated the data such that the true underlying per-protocol effect is null and under varying degrees of confounding (strong, moderate, weak). In the simulated data, we estimated per-protocol survival curves and associated contrasts using inverse probability weighting under monthly measurement of the time-varying covariates (which constituted complete measurement in our simulation), yearly measurement, as well as 3- and 6-month intervals. RESULTS: Using inverse probability weighting, we were able to recover the true null under the complete measurement scenario no matter the strength of confounding. Under yearly measurement intervals, the estimate of the per-protocol effect diverged from the null; inverse probability weighted estimates of the per-protocol 5-year risk ratio based on yearly measurement were 1.19, 1.12, and 1.03 under strong, moderate, and weak confounding, respectively. Bias decreased with measurement interval length. Under all scenarios, inverse probability weighted estimators were considerably less biased than a naive estimator that ignored time-varying confounding completely. CONCLUSIONS: Bias that arises from interval measurement designs highlights the need for planning in the design of randomized trials for collection of time-varying covariate data. This may come from more frequent in-person measurement or external sources (e.g., electronic medical record data). Such planning will provide improved estimates of the per-protocol effect through the use of methods that appropriately adjust for time-varying confounders.

摘要

背景:随机试验被认为是推断治疗效果因果关系的黄金标准。然而,当方案偏离发生时,试验的基线随机化不再足以确保协议效果的无偏估计:在随机化后,必须充分测量和调整随时间变化的混杂因素,并在分析中进行调整。鉴于历史上对随机试验意向治疗效果的重视,对随机化后混杂因素的测量通常不频繁。即使使用适当考虑过去治疗影响的时间变化混杂因素的逆概率加权等方法,也可能会导致协议效果估计的偏差。

方法/设计:为了具体说明由于时间变化的协变量测量不频繁而导致的偏差的潜在幅度,我们从一项具有生存结局和受过去治疗影响的时间变化混杂的大型试验中模拟数据。我们生成的数据使得真实的协议效果为零,并且在不同程度的混杂(强、中、弱)下。在模拟数据中,我们使用逆概率加权估计协议生存曲线和相关对比,每月测量时间变化的协变量(在我们的模拟中构成完全测量),每年测量,以及 3 个月和 6 个月间隔。

结果:使用逆概率加权,无论混杂程度如何,我们都能够在完全测量的情况下恢复真实的零值。在每年测量的间隔下,协议效果的估计值与零值偏离;基于每年测量的逆概率加权估计的协议 5 年风险比分别为强、中、弱混杂下的 1.19、1.12 和 1.03。测量间隔长度越短,偏差越小。在所有情况下,逆概率加权估计量都比完全忽略时间变化混杂的简单估计量偏差小得多。

结论:间隔测量设计引起的偏差突出表明,在设计随机试验时需要进行规划,以便收集随时间变化的协变量数据。这可能来自更频繁的面对面测量或外部来源(例如,电子病历数据)。这种规划将通过使用适当调整时间变化混杂因素的方法来提高协议效果的估计值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/f9276c6e4b8b/13063_2019_3577_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/f0881038cb66/13063_2019_3577_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a5805e00d962/13063_2019_3577_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a80ea61df6ce/13063_2019_3577_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/1df8f2aee865/13063_2019_3577_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/8f233c25ec91/13063_2019_3577_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a874dc58897f/13063_2019_3577_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/f9276c6e4b8b/13063_2019_3577_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/f0881038cb66/13063_2019_3577_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a5805e00d962/13063_2019_3577_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a80ea61df6ce/13063_2019_3577_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/1df8f2aee865/13063_2019_3577_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/8f233c25ec91/13063_2019_3577_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/a874dc58897f/13063_2019_3577_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/575d/6729016/f9276c6e4b8b/13063_2019_3577_Fig7_HTML.jpg

相似文献

[1]
Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.

Trials. 2019-9-5

[2]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[3]
Bias of time-varying exposure effects due to time-varying covariate measurement strategies.

Pharmacoepidemiol Drug Saf. 2022-1

[4]
Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial.

Clin Trials. 2020-10

[5]
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Crit Rev Food Sci Nutr. 2010

[6]
Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.

Stat Methods Med Res. 2017-11-8

[7]
Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study.

BMC Med Res Methodol. 2023-1-17

[8]
Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies.

Stat Methods Med Res. 2004-2

[9]
Statistical considerations in the design and analysis of non-inferiority trials with binary endpoints in the presence of non-adherence: a simulation study.

Wellcome Open Res. 2020-4-24

[10]
Generalizing the per-protocol treatment effect: The case of ACTG A5095.

Clin Trials. 2018-10-17

引用本文的文献

[1]
Estimating the Effects of Lifestyle Interventions on Mortality Among Cancer Survivors: A Methodologic Framework.

Epidemiology. 2025-9-1

[2]
Effect of Incident Stroke on Dementia Risk Over 10 Years in a Cohort of Asian American and Non-Latino White Older Adults in California.

Neurology. 2025-4-8

[3]
Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.

Ann Intern Med. 2024-8

[4]
Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis.

PLoS One. 2024

[5]
Why estimands are needed to define treatment effects in clinical trials.

BMC Med. 2023-7-27

[6]
Sustained Hypothetical Interventions on Midlife Alcohol Consumption in Relation to All-Cause and Cancer Mortality: The Australian Longitudinal Study on Women's Health.

Am J Epidemiol. 2024-1-8

[7]
A 40-year study of child maltreatment over the early life course predicting psychiatric morbidity, using linked birth cohort and administrative health data: protocol for the Childhood Adversity and Lifetime Morbidity (CALM) study.

BJPsych Open. 2023-3-7

[8]
MULTIPLY ROBUST ESTIMATORS OF CAUSAL EFFECTS FOR SURVIVAL OUTCOMES.

Scand Stat Theory Appl. 2022-9

[9]
Invited Commentary: Conducting and Emulating Trials to Study Effects of Social Interventions.

Am J Epidemiol. 2022-7-23

[10]
Analysis approaches to address treatment nonadherence in pragmatic trials with point-treatment settings: a simulation study.

BMC Med Res Methodol. 2022-2-16

本文引用的文献

[1]
Per-Protocol Analyses of Pragmatic Trials.

N Engl J Med. 2017-10-5

[2]
The prevention and treatment of missing data in clinical trials.

N Engl J Med. 2012-10-4

[3]
Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content.

Int J Biostat. 2010

[4]
Beyond the intention-to-treat in comparative effectiveness research.

Clin Trials. 2011-9-23

[5]
Causal inference from longitudinal studies with baseline randomization.

Int J Biostat. 2008-10-19

[6]
Observation plans in longitudinal studies with time-varying treatments.

Stat Methods Med Res. 2009-2

[7]
Comparison of dynamic treatment regimes via inverse probability weighting.

Basic Clin Pharmacol Toxicol. 2006-3

[8]
Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Biometrics. 2000-9

[9]
Correction for non-compliance in equivalence trials.

Stat Med. 1998-2-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索